📣 VC round data is live. Check it out!

IBA Group Valuation Multiples

Discover IBA Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like MiMedx Group, Cerus, Cytek Biosciences, Polynovo and more.

IBA Group Overview

About IBA Group

Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World.


Founded

1986

HQ

Belgium

Employees

2.1K

Financials (LTM)

Revenue: $724M
EBITDA: $55M

EV

$594M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

IBA Group Financials

IBA Group reported last 12-month revenue of $724M and EBITDA of $55M.

In the same LTM period, IBA Group generated $55M in EBITDA and $19M in net income.

Revenue (LTM)


IBA Group P&L

In the most recent fiscal year, IBA Group reported revenue of $722M and EBITDA of $52M.

IBA Group is profitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 7%, and net margin of 2%.

See analyst estimates for IBA Group
LTMLast FY202320242025202620272028
Revenue$724M$722M$499M$580M$722M
Gross Profit-$232M$156M$193M$232M
Gross Margin-32%31%33%32%
EBITDA$55M$52M$15M$33M$43M
EBITDA Margin8%7%3%6%6%
EBIT Margin5%4%1%2%4%
Net Profit$19M$15M($11M)$11M$15M
Net Margin3%2%(2%)2%2%
Net Debt-$27M---

Financial data powered by Morningstar, Inc.

IBA Group Stock Performance

IBA Group has current market cap of $534M, and enterprise value of $594M.

Market Cap Evolution


IBA Group's stock price is $18.34.

IBA Group share price increased by 39.2% in the last year.

IBA Group has an EPS (earnings per share) of $0.51.

See more trading valuation data for IBA Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$594M$534M0.1%0.0%19.6%39.2%$0.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

IBA Group Valuation Multiples

IBA Group trades at 0.8x EV/Revenue multiple, and 10.8x EV/EBITDA.

See NTM and 2027E valuation multiples for IBA Group

EV / Revenue (LTM)


IBA Group Financial Valuation Multiples

As of June 3, 2026, IBA Group has market cap of $534M and EV of $594M.

IBA Group has a P/E ratio of 27.8x.

LTMLast FY202320242025202620272028
EV/Revenue0.8x0.8x1.2x1.0x0.8x
EV/EBITDA10.8x11.4x40.7x17.7x14.0x
EV/EBIT16.7x18.8x95.5x51.6x23.0x
EV/Gross Profit-2.6x3.8x3.1x2.6x
P/E27.8x36.0x(50.4x)49.6x36.0x
EV/FCF-(13.3x)(15.9x)(28.3x)(13.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified IBA Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

IBA Group Margins & Growth Rates

IBA Group grew revenue by 2% and EBITDA by 13% in the last fiscal year.

In the most recent fiscal year, IBA Group reported gross margin of 32%, EBITDA margin of 7%, and net margin of 2%.

See estimated margins and future growth rates for IBA Group

IBA Group Margins

Last FY202420252026202720282029
Gross Margin32%33%32%-
EBITDA Margin7%6%6%8%
EBIT Margin4%2%4%6%
Net Margin2%2%2%3%
FCF Margin(6%)(4%)(6%)-

IBA Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%16%24%2%
Gross Profit Growth-23%20%-
EBITDA Growth13%130%27%39%
EBIT Growth29%85%124%58%
Net Profit Growth71%(202%)38%71%
FCF Growth-(44%)113%-

Data powered by FactSet, Inc. and Morningstar, Inc.

IBA Group Operational KPIs

IBA Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

IBA Group's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IBA Group's Rule of X is 14% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for IBA Group
LTMLast FY202320242025202620272028
Rule of 4010%10%---
Bessemer Rule of X14%14%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-5%6%6%5%
G&A Expenses to Revenue-13%13%12%13%
R&D Expenses to Revenue-10%11%12%10%
Opex to Revenue-29%30%31%29%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

IBA Group Competitors

IBA Group competitors include MiMedx Group, Cerus, Cytek Biosciences, Polynovo, Bioventus, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline and 2seventy bio.

Most IBA Group public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
MiMedx Group0.9x1.1x3.7x6.4x
Cerus2.4x2.3x58.8x40.6x
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Polynovo5.9x5.0x72.0x57.2x
Bioventus1.4x1.3x6.8x6.7x
Tactile Medical1.4x1.4x10.6x10.1x
Sofwave Medical6.0x-68.7x-
NeuroPace5.7x5.7x(114.3x)(86.6x)

This data is available for Pro users. Sign up to see all IBA Group competitors and their valuation data.

Start Free Trial

Acquisitions by IBA Group

IBA Group has acquired 3 companies to date.

Last acquisition by IBA Group was on December 19th 2025. IBA Group acquired Optimized Radiochemical Applications for $22M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by IBA Group

Optimized Radiochemical Applications
PhantomX
Radcal
Description
Optimized Radiochemical Applications produces sterile injectable PET radiopharmaceuticals and supplies automated synthesizers for nuclear medicine imaging.
PhantomX is a Berlin-based supplier of anthropomorphic phantoms for medical imaging validation and AI training. Its models simulate human tissues for CT, MRI, and ultrasound, incorporating contrast agents and lesions. Used by radiology departments at Charité Hospital since 2018, PhantomX supports dosimetry and algorithm certification.
Santa Fe Springs-headquartered Radcal is a provider of radiation dosimetry instruments for X-ray quality assurance in medical imaging facilities. Its product line includes the Accu-Gold dosimeters and RaySafe X2 analyzers used in over 10,000 hospitals globally. Founded in 1985, Radcal calibrates equipment for CT, mammography, and fluoroscopy systems, complying with IEC 61223 standards.
HQ CountryBelgiumGermanyUnited States
HQ City
-
Berlin
Los Angeles, CA
Deal Date19 Dec 20253 Nov 20259 Feb 2024
Valuation$22Mundisclosed$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IBA Group acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by IBA Group

IBA Group has invested in 3 companies to date.

Latest investment by IBA Group was on April 28th 2025. IBA Group invested in Signatur Biosciences in their $7M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by IBA Group

Signatur Biosciences
PanTera
Hil Applied Medical
Description
Signatur Biosciences is a 2022-founded molecular diagnostics company in Oslo developing proteomics-based tests for precision medicine in oncology and infectious diseases across Scandinavia.
PanTera is a Belgian biotech firm producing actinium-225 radioisotopes for alpha-emitting cancer radiopharmaceuticals. The company scales extraction from radium-226 precursors and recycles waste streams for sustainability. Headquartered in Ghent since 2020, PanTera supplies clinical trials for prostate and leukemia treatments through partnerships with European pharma developers.
Jerusalem-headquartered HIL Applied Medical develops ultra-compact proton therapy accelerators through a patented method integrating nanotechnology, ultra-high-intensity lasers, and ultra-fast magnets. This technology shrinks system size, complexity, and costs to deliver single-room treatment solutions. The privately held firm receives backing from venture capital investors and global strategic partners while operating a wholly owned subsidiary in Reno, Nevada.
HQ CountryUnited StatesBelgiumIsrael
HQ City
New York City, NY
Mol
Jerusalem
Deal Date28 Apr 202511 Sep 202423 Aug 2016
RoundSeedSeries AStrategic investment
Raised$7M$112M$2M
InvestorsIBA Group; NoshaqEQT; Eurazeo; IBA Group; Korys; Kurma Partners; Paladin; PMV; SFPIMIBA Group
Valuationundisclosed$313Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IBA Group investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About IBA Group

When was IBA Group founded?IBA Group was founded in 1986.
Where is IBA Group headquartered?IBA Group is headquartered in Belgium.
How many employees does IBA Group have?As of today, IBA Group has over 2K employees.
Who is the CEO of IBA Group?IBA Group's CEO is Olivier Legrain.
Is IBA Group publicly listed?Yes, IBA Group is a public company listed on Euronext Brussels.
What is the stock symbol of IBA Group?IBA Group trades under IBAB ticker.
When did IBA Group go public?IBA Group went public in 1998.
Who are competitors of IBA Group?IBA Group main competitors include MiMedx Group, Cerus, Cytek Biosciences, Polynovo, Bioventus, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline, 2seventy bio.
What is the current market cap of IBA Group?IBA Group's current market cap is $534M.
What is the current revenue of IBA Group?IBA Group's last 12 months revenue is $724M.
What is the current revenue growth of IBA Group?IBA Group revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of IBA Group?Current revenue multiple of IBA Group is 0.8x.
What is the current EBITDA of IBA Group?IBA Group's last 12 months EBITDA is $55M.
What is IBA Group's EBITDA margin?IBA Group's last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of IBA Group?Current EBITDA multiple of IBA Group is 10.8x.
How many companies IBA Group has acquired to date?As of June 2026, IBA Group has acquired 3 companies.
What was the largest acquisition by IBA Group?$22M acquisition of Optimized Radiochemical Applications on 19th December 2025 was the largest M&A IBA Group has done to date.
What companies IBA Group acquired?IBA Group acquired Optimized Radiochemical Applications, Radcal, and PhantomX.
In how many companies IBA Group has invested to date?As of June 2026, IBA Group has invested in 3 companies.
What was the last IBA Group investment?On 28th April 2025 IBA Group invested in Signatur Biosciences, participating in a $7M Seed round, alongside Noshaq.
In what companies IBA Group invested in?IBA Group invested in PanTera, Signatur Biosciences, and Hil Applied Medical.

See public comps similar to IBA Group

Lists including IBA Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial